2016 EHA: Phase 1 dose-escalation study of ASTX727: comparable variability in pharmacokinetics

Summary

Hypomethylating agents (HMA) are typically administered parenterally and adjusted to body surface area (BSA) in order to achieve target pharmacokinetic (PK) parameters associated with response. Much of the variation associated with administration of HMAs is related to the intrinsic activity of cytidine deaminase (CDA) an enzyme which rapidly metabolizes HMAs and is highest in the gut and liver. We report here intra-and inter-patient pharmacokinetic variation in patients from a study aiming to match PK parameters of BSA adjusted dosing with IV decitabine (DAC) with a novel fixed-dose oral combination (ASTX727), of DAC and E7727, a CDA inhibitor. Preliminary safety and clinical activity were previously reported and are updated here.

View further details below

EHA: Phase 1 dose-escalation study of ASTX727: comparable variability in pharmacokinetics